Fig. 1, • " Fig. 5) is suggested in patients with NSCLC and an abnormal mediastinum by CT or CT-PET (Recommendation grade D).This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited. Definitions! Combined endosonography EBUS-TBNA and EUS-(B)-FNA combined Complete mediastinal nodal staging All nodes evaluated (in contrast to only analysis of suspected nodes based on CT and/or PET imaging) Targeted mediastinal nodal staging Evaluation of the node(s) that is (are) suspicious on CT and/or PET Centrally located lung tumor Lung tumor located within the inner third of the chest Peripherally located lung cancer Lung tumor located within the outer two thirds of the chest Lymph node(s) suspicious for malignancy (abnormal mediastinum) Node with a short axis (> 10 mm) and/or that is FDG-PET-avid

This is an official guideline of the European Society of Gastrointestinal Endoscopy (ESGE), produced in cooperation with the European Respiratory Society (ERS) and the European Society of Thoracic Surgeons (ESTS). It addresses the benefit and burden associated with combined endobronchial and esophageal mediastinal nodal staging of lung cancer. The Scottish Intercollegiate Guidelines Network (SIGN) approach was adopted to define the strength of recommendations and the quality of evidence. The article has been co-published with permission in the European Journal of Cardio-Thoracic Surgery and the European Respiratory Journal. Combined endosonography EBUS-TBNA and EUS-(B)-FNA combined Complete mediastinal nodal staging All nodes evaluated (in contrast to only analysis of suspected nodes based on CT and/or PET imaging) Targeted mediastinal nodal staging Evaluation of the node(s) that is (are) suspicious on CT and/or PET Centrally located lung tumor Lung tumor located within the inner third of the chest Peripherally located lung cancer Lung tumor located within the outer two thirds of the chest Lymph node(s) suspicious for malignancy (abnormal mediastinum) Node with a short axis (> 10 mm) and/or that is FDG-PET-avid Vilmann Peter et al. Combined endobronchial and esophageal endosonography for the diagnosis and staging of lung cancer

This is an official guideline of the European Society of Gastrointestinal Endoscopy (ESGE), produced in cooperation with the European Respiratory Society (ERS) and the European Society of Thoracic Surgeons (ESTS). It addresses the benefit and burden associated with combined endobronchial and esophageal mediastinal nodal staging of lung cancer. The Scottish Intercollegiate Guidelines Network (SIGN) approach was adopted to define the strength of recommendations and the quality of evidence.The article has been co-published with permission in Endoscopy and the European Respiratory Journal.

No abstract

Aim To compare the peri- and postoperative data between a hybrid minimally invasive esophagectomy (HMIE) and the conventional Ivor Lewis esophagectomy. Methods Retrospective comparison of perioperative characteristics, postoperative complications, and survival between HMIE and Ivor Lewis esophagectomy. Results 216 patients were included, with 160 procedures performed with the conventional and 56 with the HMIE approach. Lower perioperative blood loss was found in the HMIE group (600 ml versus 200 ml, p < 0.001). Also, a higher median number of lymph nodes were harvested in the HMIE group (median 28) than in the conventional group (median 23) (p = 0.002). The median length of stay was longer in the conventional group compared to the HMIE group (11.5 days versus 10.0 days, p = 0.03). Patients in the HMIE group experienced fewer grade 2 or higher complications than the conventional group (39% versus 57%, p = 0.03). The rate of all pulmonary (51% versus 43%, p = 0.32) and severe pulmonary complications (38% versus 18%, p = 0.23) was not statistically different between the groups. Conclusions The HMIE was associated with lower intraoperative blood loss, a higher lymph node harvest, and a shorter hospital stay. However, the inborn limitations with the retrospective design stress a need for prospective randomized studies. Registration number is DRKS00013023.